AstraZeneca Moves Into Obesity With Eye On Combinations

 
• By Jessica Merrill

The company licensed an oral GLP-1 agonist from Eccogene, hoping to capitalize on its heritage in cardiovascular disease. AstraZeneca also reported third quarter results.

combination drugs
AstraZeneca is interested in developing combination drugs in obesity • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas